| pubmed-article:11033768 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C0024109 | lld:lifeskim |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C0026724 | lld:lifeskim |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C0014457 | lld:lifeskim |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C0700624 | lld:lifeskim |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C0205373 | lld:lifeskim |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:11033768 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:11033768 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:11033768 | pubmed:dateCreated | 2001-1-16 | lld:pubmed |
| pubmed-article:11033768 | pubmed:abstractText | The relative efficacy of mucosal (intratracheal) and systemic (intraperitoneal) delivery of interleukin (IL)-12 was evaluated in a mouse model of allergic lung eosinophilia. Mucosal administration of IL-12 achieved 100- to 600-fold higher bronchoalveolar lavage (BAL) levels of IL-12, but 2- to 10-fold lower serum levels compared to systemic administration. Whereas both mucosal and systemic IL-12 inhibited BAL eosinophil recruitment at high doses (100-1000 ng), only mucosal IL-12 was effective at low doses (1-10 ng). Mucosal, but not systemic, administration of 1000 ng of IL-12 increased interferon (IFN)-gamma expression in BAL cells. In a model of ongoing eosinophilic inflammation, when mucosal or systemic IL-12 doses were initiated prior to peak eosinophilia, further eosinophil recruitment was inhibited. However, when IL-12 treatment was initiated after peak eosinophil recruitment occurred, recovery from eosinophilic inflammation was not facilitated. Our findings are the first to demonstrate that locally administered IL-12 inhibits eosinophil recruitment at 100-fold lower doses than systemic IL-12. The most likely mechanism of this enhanced inhibitory activity is a sustained increase in lung levels of IL-12 that augments IFN-gamma production from BAL cells. We suggest that future studies should evaluate the efficacy of low doses of nebulized IL-12 in inhibiting eosinophilic lung inflammation in asthma. | lld:pubmed |
| pubmed-article:11033768 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033768 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11033768 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033768 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11033768 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033768 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033768 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033768 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033768 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033768 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11033768 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:11033768 | pubmed:issn | 0190-2148 | lld:pubmed |
| pubmed-article:11033768 | pubmed:author | pubmed-author:WiltJ CJC | lld:pubmed |
| pubmed-article:11033768 | pubmed:author | pubmed-author:SunRR | lld:pubmed |
| pubmed-article:11033768 | pubmed:author | pubmed-author:BouchardPP | lld:pubmed |
| pubmed-article:11033768 | pubmed:author | pubmed-author:DAYR GRG | lld:pubmed |
| pubmed-article:11033768 | pubmed:author | pubmed-author:SurSS | lld:pubmed |
| pubmed-article:11033768 | pubmed:author | pubmed-author:HolbertDD | lld:pubmed |
| pubmed-article:11033768 | pubmed:author | pubmed-author:Van ScottM... | lld:pubmed |
| pubmed-article:11033768 | pubmed:author | pubmed-author:ChoudhuryB... | lld:pubmed |
| pubmed-article:11033768 | pubmed:author | pubmed-author:AlamRR | lld:pubmed |
| pubmed-article:11033768 | pubmed:author | pubmed-author:SigounasAA | lld:pubmed |
| pubmed-article:11033768 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11033768 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:11033768 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11033768 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11033768 | pubmed:pagination | 457-76 | lld:pubmed |
| pubmed-article:11033768 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:meshHeading | pubmed-meshheading:11033768... | lld:pubmed |
| pubmed-article:11033768 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11033768 | pubmed:articleTitle | Mucosal IL-12 is more effective than systemic IL-12 in augmenting IFN-gamma expression and inhibiting allergic lung eosinophilia in murine lungs. | lld:pubmed |
| pubmed-article:11033768 | pubmed:affiliation | Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555-0762, USA. Sasur@utmb.edu | lld:pubmed |
| pubmed-article:11033768 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11033768 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11033768 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11033768 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11033768 | lld:pubmed |
